Cytosorbents
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cytosorbents generated cash of -$21,655,136, which is more than the previous year. Cash used in financing activities reached the amount of $14,474,210 last year. Net change in cash is therefore -$8,216,931.
Cash Flow
| 2014 | -6.66M | -2.31M | 10.01M |
|---|---|---|---|
| 2015 | -9.00M | -890.9K | 11.64M |
| 2016 | -6.73M | 1.59M | 5.06M |
| 2017 | -6.46M | -1.67M | 20.12M |
| 2018 | -10.83M | -1.52M | 17.46M |
| 2019 | -16.75M | -1.52M | 8.17M |
| 2020 | -5.61M | -1.67M | 66.34M |
| 2021 | -14.00M | -4.28M | 715.19K |
| 2022 | -28.23M | -6.45M | 4.95M |
| 2023 | -21.65M | -936.23K | 14.47M |
CTSO Cash Flow Statement (2014 โ 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 23.83M | 53.82M | 71.42M | 12.23M | 22.36M | 17.32M | 5.24M | 5.31M | 3.60M | 2.18M |
Operating activities | ||||||||||
Net income | -28.50M | -32.81M | -24.55M | -7.83M | -19.26M | -17.21M | -8.46M | -11.93M | -8.13M | -9.32M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.02M | 1.13M | 1.12M | 660.78K | 581.53K | 390.55K | 218.27K | 161.61K | 112.96K | 65.54K |
Stock-based compensation expense | 3.70M | 3.80M | 6.20M | 4.70M | 2.83M | 0 | 3.31M | 2.75M | 382.28K | 695.84K |
| Deferred income tax benefit | 3.70M | 3.80M | 6.20M | 4.70M | 2.83M | 0 | 3.31M | 2.75M | 382.28K | 695.84K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -245.61K | -1.28M | 420.57K | -326.86K | -642.17K | -1.84M | -649.31K | -889.71K | 131.97K | -412.11K |
Inventories | -121.03K | 945.35K | -2.35M | -461.51K | -1.28M | -56.75K | 57.32K | 340.39K | -632.53K | -303.12K |
Accounts payable | 1.62M | -3.24T | 2.42M | 1.42T | 470.55K | 1.70M | 523.37K | 2.06M | -83.16K | 497.45K |
Cash generated by operating activities | -21.65M | -28.23M | -14.00M | -5.61M | -16.75M | -10.83M | -6.46M | -6.73M | -9.00M | -6.66M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.67M | -6.68M |
Investments In Property Plant And Equipment | -538.11K | -6.45M | -4.28M | -1.67M | -1.52M | -1.52M | -1.67M | -595.53K | -643.44K | -367.32K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 239.83K | 214.16K |
Cash generated by investing activities | -936.23K | -6.45M | -4.28M | -1.67M | -1.52M | -1.52M | -1.67M | 1.59M | -890.9K | -2.31M |
Financing activities | ||||||||||
Common Stock Issued | 14.25M | -40.35K | 715.19K | 80.21M | 673.65K | 14.12M | 13.67M | 0 | 9.52M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | -335.73K | 0 | 0 | 0 |
Repurchases of common stock | 0 | -40.35K | -90K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 5M | 0 | -16.41M | 5M | -666.66K | 5M | 0 | 0 | 0 |
Cash used in financing activities | 14.47M | 4.95M | 715.19K | 66.34M | 8.17M | 17.46M | 20.12M | 5.06M | 11.64M | 10.01M |
Net Change In Cash | -8.21M | -29.99M | -17.59M | 59.18M | -10.13M | 5.04M | 12.07M | -71.67K | 1.71M | 1.42M |
Cash at end of period | 15.61M | 23.83M | 53.82M | 71.42M | 12.23M | 22.36M | 17.32M | 5.24M | 5.31M | 3.60M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |